You are viewing: UAE AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The UAE AI in Life Science Market was valued at $111.48 Million in 2026 and projected to reach to $349.33 Million by 2031, representing a compound annual growth rate of CAGR 25.7%. The UAE AI in Life Science market is poised for substantial growth through 2031, driven by government initiatives promoting healthcare innovation and digital transformation.

UAE AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UAE AI in Life Science Market Trends and Insights

  • The UAE's strategic investments in healthcare innovation and digital transformation are driving adoption of AI-powered solutions across drug discovery, diagnostics, and personalized medicine.
  • The UAE's position as a regional hub for advanced healthcare technology and government support for AI initiatives are accelerating market penetration. The UAE's life science sector is leveraging AI to enhance research capabilities, streamline clinical workflows, and improve patient outcomes.
  • Between 2026 and 2031, the UAE is expected to see significant growth in AI applications for genomics, biomarker identification, and clinical trial optimization.
  • The UAE's robust healthcare infrastructure and investment in smart city initiatives position the nation as a leader in AI-driven life science innovation across the Middle East and Africa region..

Key Market Statistics

  • CAGR (2026-2031) CAGR 25.7%
  • Market Size, 2026 ~USD 111.48 Million
  • Forecast, 2031 ~USD 349.33 Million
  • Country UAE

UAE AI in Life Science Market Overview

Rapid Market Growth :

UAE's AI in Life Science market is expanding at 25.7% CAGR, growing from $111.48 million in 2026 to $349.33 million by 2031, outpacing many regional markets.

Government-Backed Innovation :

UAE's strategic investments in healthcare digital transformation and AI adoption are creating a favorable ecosystem for life science companies and healthcare providers.

Regional Healthcare Hub :

The UAE's position as a regional center for advanced healthcare attracts international biotech firms and enables rapid deployment of AI-powered diagnostic and drug discovery solutions.

Diverse Application Areas :

AI adoption spans drug discovery, personalized medicine, clinical diagnostics, and patient management systems across UAE's private and public healthcare sectors.

UAE AI in Life Science Market Dynamics

  • The emirate's investment in smart healthcare infrastructure and partnerships with global biotech leaders are accelerating AI adoption across diagnostics, drug discovery, and personalized medicine platforms.
  • With strong healthcare spending and a focus on becoming a regional medical innovation hub, UAE presents significant opportunities for AI solution providers.
  • The market's 25.7% CAGR reflects increasing demand from hospitals, research institutions, and pharmaceutical companies seeking competitive advantages through advanced analytics and intelligent automation..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • The UAE AI in Life Science Market will grow from $111.48M (2026) to $349.33M (2031), representing a 25.7% CAGR.
    • The UAE's government-backed AI and healthcare initiatives are creating a favorable ecosystem for life science technology adoption.
    • The UAE is emerging as a regional innovation hub, attracting biotech companies and research institutions focused on AI-driven solutions.
    • The UAE's investment in smart healthcare infrastructure is driving demand for AI applications in diagnostics, drug discovery, and personalized medicine.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    UAE AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    UAE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES4.635.717.189.0811.3314.2617.8422.0525.1
    BIOTECHNOLOGY COMPANIES15.8719.6924.9231.739.8250.4863.5679.0826
    CRO & CDMO10.8613.4116.8721.3426.6633.6242.0952.0825.3
    DIAGNOSTIC COMPANIES7.188.8911.2314.2617.8822.6128.4235.2825.7
    OTHER END USERS3.223.954.946.217.719.6612.0214.7724.5
    PHARMACEUTICAL COMPANIES29.5836.6646.3358.8573.8493.49117.56146.0725.8
    TOTAL71.3488.32111.48141.42177.24224.13281.48349.3325.7

    Target Audience

    • Healthcare Providers & Hospitals : UAE hospitals and clinics need market intelligence to evaluate AI solution investments, benchmark against regional peers, and optimize diagnostic and treatment capabilities.
    • Pharmaceutical & Biotech Companies : Life science firms require UAE-specific market data to assess drug discovery opportunities, identify partnership prospects, and plan regional expansion strategies.
    • AI & Software Solution Vendors : Technology companies need detailed UAE market insights to position AI products, understand healthcare buyer requirements, and prioritize market entry investments.
    • Investment & Private Equity Firms : Investors evaluating healthcare AI opportunities in the Middle East need UAE market forecasts and growth drivers to make informed funding and acquisition decisions.
    • Government & Healthcare Policymakers : UAE health authorities and innovation agencies require market data to guide digital health strategy, allocate resources, and measure progress toward healthcare transformation goals.

    Key Companies in the UAE AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise valuation ($111.48M in 2026) and forecast projections ($349.33M by 2031) specific to UAE, enabling accurate business planning and investment decisions.
    • Competitive Landscape Intelligence : Understand UAE-specific market dynamics, key players, and regional competitive positioning to identify partnership and expansion opportunities in this high-growth market.
    • Sector-Specific Insights : Gain detailed analysis of AI applications in UAE's drug discovery, diagnostics, and personalized medicine segments to target the most promising market segments.
    • Government & Policy Context : Learn about UAE's healthcare innovation initiatives, regulatory environment, and digital transformation roadmap that are shaping market opportunities and investment climate.
    • Strategic Market Entry : Develop informed go-to-market strategies for UAE with localized insights on healthcare provider adoption rates, technology preferences, and regional buyer behavior patterns.

    Frequently asked questions

    What is the current size of the UAE AI in Life Science Market?

    The UAE AI in Life Science Market is valued at $111.48 million in 2026 and is projected to grow to $349.33 million by 2031.

    What is the expected growth rate for AI in Life Science in the UAE?

    The UAE AI in Life Science Market is expected to grow at a compound annual growth rate (CAGR) of 25.7% from 2026 to 2031.

    What are the primary drivers of AI adoption in the UAE's life science sector?

    The UAE's primary drivers include government support for AI initiatives, investments in smart healthcare infrastructure, regional positioning as a biotech hub, and increasing demand for personalized medicine and advanced diagnostics.

    Which AI applications are most prominent in the UAE's life science market?

    The UAE's life science sector is focusing on AI applications in drug discovery, genomics analysis, clinical diagnostics, biomarker identification, and clinical trial optimization.

    How does the UAE's market compare to other regions in the Middle East and Africa?

    The UAE is positioned as a leading market in the Middle East and Africa region due to its advanced healthcare infrastructure, government backing for AI innovation, and strategic investments in life science technology.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status